Union Savings Bank Increases Holdings in GSK plc (NYSE:GSK)

Union Savings Bank raised its stake in shares of GSK plc (NYSE:GSK) by 15.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,928 shares of the pharmaceutical company’s stock after buying an additional 398 shares during the period. Union Savings Bank’s holdings in GSK were worth $109,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Versant Capital Management Inc boosted its holdings in GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 676 shares during the period. Larson Financial Group LLC boosted its holdings in GSK by 271.8% in the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 647 shares during the period. BKM Wealth Management LLC bought a new position in GSK in the 4th quarter worth $32,000. Jones Financial Companies Lllp boosted its holdings in GSK by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after buying an additional 509 shares during the period. Finally, Princeton Global Asset Management LLC boosted its holdings in GSK by 54.3% in the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after buying an additional 533 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Price Performance

Shares of GSK traded down $0.69 during midday trading on Thursday, hitting $45.09. 1,061,494 shares of the company traded hands, compared to its average volume of 3,508,417. The firm has a 50 day moving average of $42.43 and a 200-day moving average of $40.02. GSK plc has a 52 week low of $33.33 and a 52 week high of $45.92. The stock has a market cap of $93.45 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 1.35 and a beta of 0.65. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.15. The firm had revenue of $9.34 billion for the quarter, compared to analysts’ expectations of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. On average, analysts forecast that GSK plc will post 4.1 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. This represents a $1.50 annualized dividend and a dividend yield of 3.34%. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio is currently 53.26%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on GSK shares. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.